<h4>Background</h4>The efficacy and safety of the administration of recombinant human thrombopoietin (rhTPO) in sepsis patients with thrombocytopenia were still inconclusive.<h4>Objectives</h4>To investigate whether rhTPO is a benefit for sepsis patients with thrombocytopenia.<h4>Methods</h4>PubMed, Cochrane library, Embase, China National Knowledge Infrastructure, and Wanfang Database were electronically searched to the randomized controlled trials (RCTs) from inception to March 4, 2020. Here, THPO is linked to Sepsis.